Cormet-Boyaka E, Huneau J F, Mordrelle A, Boyaka P N, Carbon C, Rubinstein E, Tomé D
INRA, Unité de Nutrition Humaine et de Physiologie Intestinale, Institut National Agronomique Paris-Grignon, 75005 Paris, France.
Antimicrob Agents Chemother. 1998 Oct;42(10):2607-11. doi: 10.1128/AAC.42.10.2607.
The mechanism of intestinal secretion of the difluorinated quinolone sparfloxacin was investigated with the epithelial cell line Caco-2 and was compared to that of the P-glycoprotein (P-gp) substrate vinblastine. The P-gp inhibitors verapamil and progesterone significantly increased the epithelial cell accumulation of both vinblastine and sparfloxacin. This increase is likely to result from an inhibition of drug secretion since both vinblastine uptake and sparfloxacin uptake are known to proceed through a passive transmembrane diffusion. The unidirectional fluxes across cell monlayers grown on permeable filters indicated that a net secretion of sparfloxacin and vinblastine occurred across Caco-2 cells. These secretions were significantly inhibited by the MDR-reversing agent verapamil. We conclude that the P-gp is likely to be involved in the intestinal elimination of the difluorinated quinolone sparfloxacin.
利用上皮细胞系Caco-2研究了二氟喹诺酮类药物司帕沙星的肠道分泌机制,并与P-糖蛋白(P-gp)底物长春碱的分泌机制进行了比较。P-gp抑制剂维拉帕米和孕酮显著增加了长春碱和司帕沙星在上皮细胞中的蓄积。这种增加可能是由于药物分泌受到抑制,因为已知长春碱摄取和司帕沙星摄取均通过被动跨膜扩散进行。通过生长在可渗透滤膜上的细胞单层的单向通量表明,司帕沙星和长春碱在Caco-2细胞上发生了净分泌。这些分泌受到多药耐药逆转剂维拉帕米的显著抑制。我们得出结论,P-gp可能参与了二氟喹诺酮类药物司帕沙星的肠道消除过程。